{"type":"trials","record":{"id":41600,"source_id":"clinicaltrials-gov","external_id":"NCT07434713","title":"EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).","brief_summary":"This prospective, observational, open-label study evaluates early treatment response to intravitreal aflibercept 8 mg in patients with exudative age-related macular degeneration. Retinal fluid dynamics assessed by optical coherence tomography and changes in best-corrected visual acuity two months after baseline are analyzed to characterize early treatment outcomes.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Insel Gruppe AG, University Hospital Bern","enrollment":50,"countries":["Switzerland"],"start_date":"2025-07-14","completion_date":"2026-03-27","last_update_date":"2026-02-27","source_url":"https://clinicaltrials.gov/study/NCT07434713","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ELEV8","age_range":"50 Years","comparator":null,"organization":"Insel Gruppe AG, University Hospital Bern","interventions":["treatment with Aflibercept 8mg (Eylea)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Fluid dynamics on OCT scans during the early treatment phase of macular degeneration with Aflibercept 8mg. — Each parti…","Proportion of patients without disease activity at month 2 after treatment start — Each participant is followed up for…","Prediction of Annual Treatment Demand in nAMD Patients at 12 Months — Each participant is followed up for two months wi…","Best-Corrected Visual Acuity (BCVA) Outcomes at Two Months Post-Treatment — Each participant is followed up for 2 month…"],"design_description":null,"source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration (AMD)","treatment with Aflibercept 8mg (Eylea)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07434713","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-07-14 to 2026-03-27","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.839Z","intervention":["treatment with Aflibercept 8mg (Eylea)"],"participants":50,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Fluid dynamics on OCT scans during the early treatment phase of macular degeneration with Aflibercept 8mg. — Each parti…","Proportion of patients without disease activity at month 2 after treatment start — Each participant is followed up for…","Prediction of Annual Treatment Demand in nAMD Patients at 12 Months — Each participant is followed up for two months wi…","Best-Corrected Visual Acuity (BCVA) Outcomes at Two Months Post-Treatment — Each participant is followed up for 2 month…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41600","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}